Literature DB >> 26842687

Treatment of Dry Eye Disease.

Leisa L Marshall1, J Michael Roach.   

Abstract

OBJECTIVE: Review of the etiology, clinical manifestations, and treatment of dry eye disease (DED). DATA SOURCES: Articles indexed in PubMed (National Library of Medicine), Iowa Drug Information Service (IDIS), and the Cochrane Reviews and Trials in the last 10 years using the key words "dry eye disease," "dry eye syndrome," "dry eye and treatment." Primary sources were used to locate additional resources. STUDY SELECTION AND DATA EXTRACTION: Sixty-eight publications were reviewed, and criteria supporting the primary objective were used to identify useful resources. DATA SYNTHESIS: The literature included practice guidelines, book chapters, review articles, original research articles, and product prescribing information for the etiology, clinical manifestations, diagnosis, and treatment of DED.
CONCLUSION: DED is one of the most common ophthalmic disorders. Signs and symptoms of DED vary by patient, but may include ocular irritation, redness, itching, photosensitivity, visual blurring, mucous discharge, and decreased tear meniscus or break-up time. Symptoms improve with treatment, but the condition is not completely curable. Treatment includes reducing environmental causes, discontinuing medications that cause or worsen dry eye, and managing contributing ocular or systemic conditions. Most patients use nonprescription tear substitutes, and if these are not sufficient, other treatment is prescribed. These treatments include the ophthalmic anti-inflammatory agent cyclosporine, punctal occlusion, eye side shields, systemic cholinergic agents, and autologous serum tears. This article reviews the etiology, symptoms, and current therapy for DED.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26842687     DOI: 10.4140/TCP.n.2016.96

Source DB:  PubMed          Journal:  Consult Pharm        ISSN: 0888-5109


  10 in total

1.  Serum eye drops for the treatment of ocular surface diseases: a systematic review and meta-analysis.

Authors:  Massimo Franchini; Mario Cruciani; Carlo Mengoli; Giuseppe Marano; Enrico Capuzzo; Ilaria Pati; Francesca Masiello; Eva Veropalumbo; Simonetta Pupella; Stefania Vaglio; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2019-05       Impact factor: 3.443

Review 2.  Effects of Aging in Dry Eye.

Authors:  Cintia S de Paiva
Journal:  Int Ophthalmol Clin       Date:  2017

3.  Changing Medical Paradigm on Inflammatory Eye Disease: Technology and Its Implications for P4 Medicine.

Authors:  Takenori Inomata; Jaemyoung Sung
Journal:  J Clin Med       Date:  2022-05-24       Impact factor: 4.964

Review 4.  The protective roles of clusterin in ocular diseases caused by obesity and diabetes mellitus type 2.

Authors:  Thaís Dantis Pereira de Campos; Kellen Cristina da Cruz Rodrigues; Rodrigo Martins Pereira; Chadi Pellegrini Anaruma; Raphael Dos Santos Canciglieri; Diego Gomes de Melo; Adelino Sanchez Ramos da Silva; Dennys Esper Cintra; Eduardo Rochete Ropelle; José Rodrigo Pauli; Leandro Pereira de Moura
Journal:  Mol Biol Rep       Date:  2021-05-25       Impact factor: 2.316

Review 5.  Evidence of Polyphenols Efficacy against Dry Eye Disease.

Authors:  Gaia Favero; Enrico Moretti; Kristína Krajčíková; Vladimíra Tomečková; Rita Rezzani
Journal:  Antioxidants (Basel)       Date:  2021-01-28

6.  Lower Serum Vitamin D Level Was Associated with Risk of Dry Eye Syndrome.

Authors:  Yi-Fang Meng; Jiong Lu; Qian Xing; Jian-Jun Tao; Pan Xiao
Journal:  Med Sci Monit       Date:  2017-05-10

7.  A Prospective, Post-Market, Multicenter Trial (CHEETAH) Suggested TearCare® System as a Safe and Effective Blink-Assisted Eyelid Device for the Treatment of Dry Eye Disease.

Authors:  Paul Karpecki; David Wirta; Smajo Osmanovic; Kavita Dhamdhere
Journal:  Clin Ophthalmol       Date:  2020-12-30

8.  Bone marrow mesenchymal stromal cells in a 3D system produce higher concentration of extracellular vesicles (EVs) with increased complexity and enhanced neuronal growth properties.

Authors:  Elmira Jalilian; Hamed Massoumi; Bianca Bigit; Sohil Amin; Eitan A Katz; Victor H Guaiquil; Khandaker N Anwar; Peiman Hematti; Mark I Rosenblatt; Ali R Djalilian
Journal:  Stem Cell Res Ther       Date:  2022-08-19       Impact factor: 8.079

9.  Borneol Is a TRPM8 Agonist that Increases Ocular Surface Wetness.

Authors:  Gui-Lan Chen; Ming Lei; Lu-Ping Zhou; Bo Zeng; Fangdong Zou
Journal:  PLoS One       Date:  2016-07-22       Impact factor: 3.240

10.  TearCare for the Treatment of Meibomian Gland Dysfunction in Adult Patients With Dry Eye Disease: A Masked Randomized Controlled Trial.

Authors:  Preeya K Gupta; Edward J Holland; John Hovanesian; Jennifer Loh; Mitchell A Jackson; Paul M Karpecki; Kavita Dhamdhere
Journal:  Cornea       Date:  2022-04-01       Impact factor: 2.651

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.